Cargando…

Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults

BACKGROUND: Neurodegenerative diseases are devastating conditions that most commonly affect individuals 65 years and older. Currently there are no effective treatments or cures for neurodegenerative diseases, and therapeutics that selectively target the underlying causes of these diseases are needed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silverman, M. H., Duggan, S., Bardelli, Geraldine, Sadler, B., Key, C., Medlock, M., Reynolds, L., Wallner, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419134/ https://www.ncbi.nlm.nih.gov/pubmed/36281667 http://dx.doi.org/10.14283/jpad.2022.71

Ejemplares similares

The epichaperome: the power of many as the power of one
por: Tai, Wang, et al.
Publicado: (2016)

Epichaperomics reveals dysfunctional chaperone protein networks
por: Woodford, Mark R., et al.
Publicado: (2023)

Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system
por: Bolaender, Alexander, et al.
Publicado: (2021)

Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
por: Joshi, Suhasini, et al.
Publicado: (2021)

The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction
por: Inda, Maria Carmen, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
por: Peterschmitt, M. Judith, et al.
Publicado: (2020)

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
por: Humeniuk, Rita, et al.
Publicado: (2023)

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
por: Li, Zhaoyang, et al.
Publicado: (2020)

Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia
por: Sugita, Mayumi, et al.
Publicado: (2021)

Unraveling the Mechanism of Epichaperome Modulation by Zelavespib: Biochemical Insights on Target Occupancy and Extended Residence Time at the Site of Action
por: Sharma, Sahil, et al.
Publicado: (2023)

Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants
por: Barth, Aline, et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
por: Chughlay, M. Farouk, et al.
Publicado: (2022)

Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects
por: Oshima, Hiroyuki, et al.
Publicado: (2015)

Pharmacokinetics, safety and tolerability of human recombinant alkaline phosphatase in healthy volunteers
por: Peters, E, et al.
Publicado: (2015)

Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers
por: Naik, Himanshu, et al.
Publicado: (2020)

Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers
por: Wu, Xiaojie, et al.
Publicado: (2021)

Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers
por: Becker, Andreas, et al.
Publicado: (2019)

A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects
por: Ahmadi, Ali R., et al.
Publicado: (2023)

Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects
por: Cawello, Willi, et al.
Publicado: (2013)

The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers
por: Naderer, Odin, et al.
Publicado: (2015)

Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects
por: Groenendaal-van de Meent, Dorien, et al.
Publicado: (2018)

Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
por: Humeniuk, Rita, et al.
Publicado: (2020)

Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects
por: Sheng, Lei, et al.
Publicado: (2021)

Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects
por: Xu, Junyu, et al.
Publicado: (2023)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
por: Jiang, Xu, et al.
Publicado: (2023)

Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults
por: Boettcher, Michael, et al.
Publicado: (2023)

Synthesis of (124)I-labeled epichaperome probes and assessment in visualizing pathologic protein-protein interaction networks in tumor bearing mice
por: Sharma, Sahil, et al.
Publicado: (2022)

Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation
por: Rodina, Anna, et al.
Publicado: (2023)

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants
por: Maden, Charlotte H., et al.
Publicado: (2018)

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
por: Sinxadi, Phumla, et al.
Publicado: (2020)

Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
por: Zou, Chan, et al.
Publicado: (2019)

Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects
por: Park, Min Young, et al.
Publicado: (2023)

A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP‐458) in Healthy Adult Volunteers
por: Lin, Tong, et al.
Publicado: (2021)

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects
por: Gu, Kenan, et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study
por: Gordon, David, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
por: Rhee, Elizabeth G., et al.
Publicado: (2018)

Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults
por: Usansky, Helen, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Tezepelumab (AMG 157) in Healthy and Atopic Dermatitis Adult Subjects
por: Parnes, Jane R., et al.
Publicado: (2019)

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
por: Al‐Karagholi, Mohammad Al‐Mahdi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c8f0m7e6r1f32bdcbfeq5r0qov